WO1996014829A1 - Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds - Google Patents

Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds Download PDF

Info

Publication number
WO1996014829A1
WO1996014829A1 PCT/US1995/014910 US9514910W WO9614829A1 WO 1996014829 A1 WO1996014829 A1 WO 1996014829A1 US 9514910 W US9514910 W US 9514910W WO 9614829 A1 WO9614829 A1 WO 9614829A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
boric acid
ophthalmically acceptable
steroidal anti
quaternary ammonium
Prior art date
Application number
PCT/US1995/014910
Other languages
French (fr)
Inventor
Suketu Dipakbhai Desai
Diane S. Nelms
Original Assignee
Alcon Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories, Inc. filed Critical Alcon Laboratories, Inc.
Priority to DE69522094T priority Critical patent/DE69522094T2/en
Priority to EP95939996A priority patent/EP0739197B1/en
Priority to DK95939996T priority patent/DK0739197T3/en
Priority to CA002180554A priority patent/CA2180554C/en
Priority to JP8509750A priority patent/JP2954356B2/en
Priority to AT95939996T priority patent/ATE203897T1/en
Priority to AU41622/96A priority patent/AU686917B2/en
Publication of WO1996014829A1 publication Critical patent/WO1996014829A1/en
Priority to HK98113829A priority patent/HK1012556A1/en
Priority to GR20010401480T priority patent/GR3036622T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Definitions

  • the present invention relates generally to ophthalmic compositions.
  • the present invention relates to the use of a polymeric quaternary ammonium compound and boric acid to provide preserved, storage-stable ⁇ o ophthalmic compositions of acidic drugs.
  • Ophthalmic formulations generally contain one or more active compounds along with excipients such as surfactants, comforting agents, complexing agents, stabilizers, buffering systems, chelating agents, viscosity agents or is gelling polymers and anti-oxidants. Ophthalmic formulations which are intended for multidose use require a preservative.
  • Organo-mercurials have been used as preservatives in ophthalmic formulations including ophthalmic solutions of acidic drugs. These organo- 2o mercurials include thimerosal, phenylmercuric acetate and phenylmercuric nitrate. Organo-mercurials, however, have limitations due to potential mercury toxicity and poor chemical stability.
  • Sorbic acid has also been used to preserve ophthalmic formulations, but a it too possesses poor chemical stability as well as poor antimicrobial activity.
  • Benzalkonium chloride is a widely used preservative in ophthalmic solutions.
  • benzalkonium chloride and other quaternary ammonium compounds are generally considered to be incompatible with ophthalmic 30 compositions of drugs with acidic groups, such as nonsteroidal antiinflammatory drugs ("NSAIDS").
  • NSAIDS nonsteroidal antiinflammatory drugs
  • U.S. Patent No. 5,1 10,493 discloses stable ophthalmic NSAID 35 formulations which do not contain organo-mercurial preservatives. Instead, the reference NSAID formulations use quaternary ammonium compounds, such as cetyltrimethylammonium bromide, cetylpyridinium chloride and preferably, benzalkonium chloride, and a stabilizing amount of a nonionic surfactant.
  • PCT application WO 94/15597 discloses the use of lauralkonium chloride, the C-
  • the present lack of a single preservative which is safe, stable, and able to meet both the United States Pharmacopoeia (USP) and European Pharmacopoeia (Ph.Eur.) preservative effectiveness requirements for ophthalmic formulations of acidic drugs has forced pharmaceutical companies to develop more than one formulation of the same drug, with each formulation containing a different preservative.
  • U.S. Patent No. 4,960,799 discloses storage stable aqueous ophthalmic compositions containing diclofenac, a nonsteroidal antiinflammatory drug, and/or its pharmaceutically acceptable salts.
  • the reference compositions include EDTA as a stabilizing agent, a solubilizer such as polyethoxylated castor oil, and a bacteriostat.
  • the preferred bacteriostats are thimerosal and sorbic acid. No mention is made of any polymeric quaternary ammonium preservative.
  • Polyquad ® and other polymeric quaternary ammonium compounds as a disinfectant and preservative in contact lens care and artificial tear solutions is known. See, for example, U.S. Patent Nos. 5,037,647; 4,525,346; and 4,407,791. None of these references disclose the use of a polymeric quaternary ammonium compound as a preservative in any formulations of ophthalmic drugs.
  • a combination of a polymeric quaternary ammonium compound such as Polyquad ® and boric acid in ophthalmic compositions of acidic drugs provides a storage-stable composition which has surprisingly good preservative efficacy.
  • This preservative combination of a polymeric quaternary ammonium compound and boric acid is useful in ophthalmic compositions of acidic drugs such as prostaglandins, antifungals, antibacterials, and diagnostic agents.
  • This preservative combination is especially useful in ophthalmic solutions of drugs containing either a carboxyl group such as non-steroidal anti-inflammatory drugs (NSAIDS) or a sulfonamide group such as antibacterial drugs.
  • NSAIDS non-steroidal anti-inflammatory drugs
  • sulfonamide group such as antibacterial drugs.
  • the present invention also relates to a method for treating or controlling ocular inflammation which comprises topically administering to the affected eye a composition comprising a NSAID, a polymeric quaternary ammonium compound and boric acid.
  • the present invention is based on the discovery that ophthalmic compositions containing a polymeric quaternary ammonium compound and boric acid may be effectively preserved by the USP and Ph.Eur. preservative effectiveness requirements despite the absence of EDTA, a conventional chelating agent known to potentiate the antimicrobial activity of preservatives such as benzalkonium chloride and sorbic acid.
  • polymeric quaternary ammonium compounds useful in the compositions of the present invention are those which have an antimicrobial effect and which are ophthalmically acceptable. Preferred compounds of this type are described in US Patents Nos. 3,931 ,319; 4,027,020; 4,407,791 ; 4,525,346; 4,836,986; 5,037,647 and 5,300,287; and PCT application WO 91 /09523 (Dziabo et al.).
  • the most preferred polymeric ammonium compound is polyquaternium-1 , otherwise known as Polyquad ® or Onamer M ® , with a number average molecular weight between 2,000 to 30,000. Preferably, the number average molecular weight is between 3,000 to 14,000.
  • the polymeric quaternary ammonium compounds are generally used in the compositions of the present invention in an amount from about 0.00001 to about 3 wt%, preferably from about 0.001 to about 0.1 wt%. Most preferably, the compositions of the present invention contain from about 0.001 to about 0.05 wt% of polymeric quaternary ammonium compounds.
  • the boric acid used in the compositions of the present invention includes not only boric acid, but also its ophthalmically acceptable acid addition salts, as well as borate-polyol complexes of the type described in US Patent No. 5,342,620 (Chowhan). In general, an amount from about 0.3 to about 5.0 wt% is used in the compositions of the present invention. It is preferred to use from about 0.3 to about 3.0 wt%, and it most preferred to use from about 0.5 to about 2.0 wt%.
  • the water soluble borate-polyol complexes useful in the compositions of the present invention preferably comprise borate and polyol in a molar ratio between about 1 : 1 and about 1 :10.
  • Suitable ophthalmic agents which may be included in the compositions of the present invention and administered via the method of the present invention include, but are not limited to, the racemic and enantiomeric forms and ophthalmically acceptable salts, amides, esters and prodrugs of the following types of drugs containing an acidic functionality such as -COOH, -SO2NH2, or SO2NHR groups: anti-glaucoma agents, such as carbonic anhydrase inhibitors, prostaglandins and prostaglandin derivatives; non-steroidal anti-inflammatory agents, including but not limited to those classified as aryl- or heteroaryl- alkanoic acids, such as diclofenac, bromfenac, flurbiprofen, suprofen, ketorolac, indomethacin and ketoprofen; anti-bacterials and anti-infectives, including sulfa drugs, such as sulfacetamide sodium, and beta-lactams such as penicillins and cephalosporin
  • compositions of the present invention may additionally include other ophthalmically acceptable components such as comfort enhancing agents, buffers (e.g., phosphate, acetate, carbonate, and citrate), other preservatives (e.g., benzalkonium chloride and individual homologs of benzalkonium chloride, parabens, chlorobutanol, and biguanides such as chlorhexidine and hydroxypropyl methyl biguanide), surfactants (e.g.
  • poloxamers such as Pluronics ® ; polysorbates such as Tweens ® ; tyloxapol; sarcosinates such as Hamposyl ® ; and polyethoxylated castor oils such as Cremophor ® ), and tonicity agents (e.g., sodium chloride, mannitol, dextrose and xylitol).
  • tonicity agents e.g., sodium chloride, mannitol, dextrose and xylitol.
  • excipients such as antioxidants, chelating agents and complexing agents may be added to the compositions of the present invention as desired or as necessary.
  • compositions of the present invention may also include viscosity modifying agents such as: cellulosic ethers, such as, hydroxypropyl methyl cellulose (HPMC), hydroxyethyl cellulose (HEC), ethyl hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, and carboxymethyl cellulose; carbomers (e.g. Carbopol ® ); polyvinyl alcohol; polyvinyl pyrrolidone; alginates; carrageenans; and guar, karaya, agarose, locust bean, tragacanth and xanthan gums.
  • concentration of such viscosity modifiers will vary between about 0.1 to about 5 wt%, but such formulations will generally have a viscosity between about 10 and about 5000 centipoise.
  • the ophthalmic compositions of the present invention may additionally contain polymers which will undergo sol-to-gel transition upon exposure to physical or chemical stimuli, such as changes in pH, ion concentration, and/or temperature.
  • polymers include but are not limited to: certain carrageenans, and gellan, locust and xanthan gums, such as those described in US Serial No. 08/108,824 (Lang et al.), US 4,861 ,760 (Mazuel et al), US 4,136,173 (Pramoda et al), US 4,136, 177 (Lin et al.), and US 4,136, 178 (Lin et al).
  • the contents of these patent applications and patents relating to the polymers cited above are hereby incorporated by reference herein.
  • the acidic drugs in the compositions of the present invention may also be encapsulated in microparticles such as microcapsules, microspheres, nanocapsule, nanospheres, and liposomes to improve comfort, and/or provide for sustained release.
  • Formulation A The preparation of Formulation A is detailed below. Formulations B and C can be prepared in similar fashion.
  • diclofenac-sodium To a tared glass vessel containing approximately 40 % final weight of purified water was added diclofenac-sodium. This mixture was stirred until the diclofenac was completely dissolved. The following ingredients were then added with stirring in the order given below, and each ingredient was completely dissolved before addition of the next ingredient: stock solution of vitamin E TPGS; tromethamine; boric acid; Polyquad ® ; mannitol; and stock solution of HPMC. Water was then added to bring the formulation to 95% of its final weight, and the pH of the formulation adjusted to between 7 and 7.4 using NaOH and/or HCI. Water was then added to bring the final weight to 100%. The resulting formulations were approximately isotonic (above 300 milliOsmoles per kilogram (mOsm/kg)).
  • the antimicrobial preservative effectiveness of the polymeric quaternary ammonium compound/boric acid combination of the present invention was determined using an organism challenge test according to the methods described in the United States Pharmacopeia (USP) and European Pharmacopoeia (Ph.Eur.).
  • Samples were inoculated with known levels of gram-positive [Staphylococcus aureus ATCC 6538) and gram-negative ⁇ Pseudomonas aeruginosa ATCC 9027 and Escherichia coli ATCC 8739) vegetative bacteria, yeast (Candida albicans ATCC 10231 ) and mold (Aspergillus niger ATCC 16404) and sampled at specified intervals to determine if the antimicrobial preservative system was capable of killing or inhibiting the propagation of organisms purposely introduced into the formulation.
  • the rate or level of antimicrobial activity determined compliance with the USP and/or Ph.Eur. preservative efficacy standards for ophthalmic preparations.
  • a B (Target) (Min)
  • a B (Target) (Min)

Abstract

Disclosed are storage-stable preserved ophthalmic compositions containing acidic drugs in combination with polymeric quaternary ammonium compounds and boric acid.

Description

PRESERVED OPHTHALMIC DRUG COMPOSITIONS CONTAINING POLYMERIC QUATERNARY AMMONIUM COMPOUNDS
, BACKGROUND OF THE INVENTION
The present invention relates generally to ophthalmic compositions. In particular, the present invention relates to the use of a polymeric quaternary ammonium compound and boric acid to provide preserved, storage-stable ιo ophthalmic compositions of acidic drugs.
Ophthalmic formulations generally contain one or more active compounds along with excipients such as surfactants, comforting agents, complexing agents, stabilizers, buffering systems, chelating agents, viscosity agents or is gelling polymers and anti-oxidants. Ophthalmic formulations which are intended for multidose use require a preservative.
Organo-mercurials have been used as preservatives in ophthalmic formulations including ophthalmic solutions of acidic drugs. These organo- 2o mercurials include thimerosal, phenylmercuric acetate and phenylmercuric nitrate. Organo-mercurials, however, have limitations due to potential mercury toxicity and poor chemical stability.
Sorbic acid, has also been used to preserve ophthalmic formulations, but a it too possesses poor chemical stability as well as poor antimicrobial activity.
Benzalkonium chloride is a widely used preservative in ophthalmic solutions. However, benzalkonium chloride and other quaternary ammonium compounds are generally considered to be incompatible with ophthalmic 30 compositions of drugs with acidic groups, such as nonsteroidal antiinflammatory drugs ("NSAIDS"). These preservative lose their ability to function as they form complexes with the charged drug compounds.
U.S. Patent No. 5,1 10,493 discloses stable ophthalmic NSAID 35 formulations which do not contain organo-mercurial preservatives. Instead, the reference NSAID formulations use quaternary ammonium compounds, such as cetyltrimethylammonium bromide, cetylpyridinium chloride and preferably, benzalkonium chloride, and a stabilizing amount of a nonionic surfactant. PCT application WO 94/15597 discloses the use of lauralkonium chloride, the C-| 2 homolog of benzalkonium chloride, in ophthalmic formulations of drugs which are incompatible with benzalkonium chloride. Unlike the mixture of alkyldimethylbenzylammonium chloride known as benzalkonium chloride, this PCT application discloses that lauralkonium chloride is compatible with acidic drug entities; apparently it does not form insoluble ion complexes with the charged drug compounds.
In some cases, the present lack of a single preservative which is safe, stable, and able to meet both the United States Pharmacopoeia (USP) and European Pharmacopoeia (Ph.Eur.) preservative effectiveness requirements for ophthalmic formulations of acidic drugs has forced pharmaceutical companies to develop more than one formulation of the same drug, with each formulation containing a different preservative.
U.S. Patent No. 4,960,799 discloses storage stable aqueous ophthalmic compositions containing diclofenac, a nonsteroidal antiinflammatory drug, and/or its pharmaceutically acceptable salts. The reference compositions include EDTA as a stabilizing agent, a solubilizer such as polyethoxylated castor oil, and a bacteriostat. The preferred bacteriostats are thimerosal and sorbic acid. No mention is made of any polymeric quaternary ammonium preservative.
The use of Polyquad® and other polymeric quaternary ammonium compounds as a disinfectant and preservative in contact lens care and artificial tear solutions is known. See, for example, U.S. Patent Nos. 5,037,647; 4,525,346; and 4,407,791. None of these references disclose the use of a polymeric quaternary ammonium compound as a preservative in any formulations of ophthalmic drugs.
SUMMARY OF THE INVENTION
It has now been discovered that the use of a combination of a polymeric quaternary ammonium compound such as Polyquad® and boric acid in ophthalmic compositions of acidic drugs provides a storage-stable composition which has surprisingly good preservative efficacy. This preservative combination of a polymeric quaternary ammonium compound and boric acid is useful in ophthalmic compositions of acidic drugs such as prostaglandins, antifungals, antibacterials, and diagnostic agents. This preservative combination is especially useful in ophthalmic solutions of drugs containing either a carboxyl group such as non-steroidal anti-inflammatory drugs (NSAIDS) or a sulfonamide group such as antibacterial drugs.
The present invention also relates to a method for treating or controlling ocular inflammation which comprises topically administering to the affected eye a composition comprising a NSAID, a polymeric quaternary ammonium compound and boric acid.
Among other factors, the present invention is based on the discovery that ophthalmic compositions containing a polymeric quaternary ammonium compound and boric acid may be effectively preserved by the USP and Ph.Eur. preservative effectiveness requirements despite the absence of EDTA, a conventional chelating agent known to potentiate the antimicrobial activity of preservatives such as benzalkonium chloride and sorbic acid.
DETAILED DESCRIPTION OF THE INVENTION
The polymeric quaternary ammonium compounds useful in the compositions of the present invention are those which have an antimicrobial effect and which are ophthalmically acceptable. Preferred compounds of this type are described in US Patents Nos. 3,931 ,319; 4,027,020; 4,407,791 ; 4,525,346; 4,836,986; 5,037,647 and 5,300,287; and PCT application WO 91 /09523 (Dziabo et al.). The most preferred polymeric ammonium compound is polyquaternium-1 , otherwise known as Polyquad® or Onamer M®, with a number average molecular weight between 2,000 to 30,000. Preferably, the number average molecular weight is between 3,000 to 14,000.
The polymeric quaternary ammonium compounds are generally used in the compositions of the present invention in an amount from about 0.00001 to about 3 wt%, preferably from about 0.001 to about 0.1 wt%. Most preferably, the compositions of the present invention contain from about 0.001 to about 0.05 wt% of polymeric quaternary ammonium compounds.
The boric acid used in the compositions of the present invention includes not only boric acid, but also its ophthalmically acceptable acid addition salts, as well as borate-polyol complexes of the type described in US Patent No. 5,342,620 (Chowhan). In general, an amount from about 0.3 to about 5.0 wt% is used in the compositions of the present invention. It is preferred to use from about 0.3 to about 3.0 wt%, and it most preferred to use from about 0.5 to about 2.0 wt%. The water soluble borate-polyol complexes useful in the compositions of the present invention preferably comprise borate and polyol in a molar ratio between about 1 : 1 and about 1 :10.
Suitable ophthalmic agents which may be included in the compositions of the present invention and administered via the method of the present invention include, but are not limited to, the racemic and enantiomeric forms and ophthalmically acceptable salts, amides, esters and prodrugs of the following types of drugs containing an acidic functionality such as -COOH, -SO2NH2, or SO2NHR groups: anti-glaucoma agents, such as carbonic anhydrase inhibitors, prostaglandins and prostaglandin derivatives; non-steroidal anti-inflammatory agents, including but not limited to those classified as aryl- or heteroaryl- alkanoic acids, such as diclofenac, bromfenac, flurbiprofen, suprofen, ketorolac, indomethacin and ketoprofen; anti-bacterials and anti-infectives, including sulfa drugs, such as sulfacetamide sodium, and beta-lactams such as penicillins and cephalosporins; and diagnostic agents such as sodium fluorescein. Combinations of ophthalmic agents may also be used in the compositions of the present invention.
The compositions of the present invention may additionally include other ophthalmically acceptable components such as comfort enhancing agents, buffers (e.g., phosphate, acetate, carbonate, and citrate), other preservatives (e.g., benzalkonium chloride and individual homologs of benzalkonium chloride, parabens, chlorobutanol, and biguanides such as chlorhexidine and hydroxypropyl methyl biguanide), surfactants (e.g. poloxamers such as Pluronics®; polysorbates such as Tweens®; tyloxapol; sarcosinates such as Hamposyl®; and polyethoxylated castor oils such as Cremophor®), and tonicity agents (e.g., sodium chloride, mannitol, dextrose and xylitol). In addition, other excipients, such as antioxidants, chelating agents and complexing agents may be added to the compositions of the present invention as desired or as necessary.
The compositions of the present invention may also include viscosity modifying agents such as: cellulosic ethers, such as, hydroxypropyl methyl cellulose (HPMC), hydroxyethyl cellulose (HEC), ethyl hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, and carboxymethyl cellulose; carbomers (e.g. Carbopol®); polyvinyl alcohol; polyvinyl pyrrolidone; alginates; carrageenans; and guar, karaya, agarose, locust bean, tragacanth and xanthan gums. The concentration of such viscosity modifiers will vary between about 0.1 to about 5 wt%, but such formulations will generally have a viscosity between about 10 and about 5000 centipoise.
The ophthalmic compositions of the present invention may additionally contain polymers which will undergo sol-to-gel transition upon exposure to physical or chemical stimuli, such as changes in pH, ion concentration, and/or temperature. Examples of such polymers include but are not limited to: certain carrageenans, and gellan, locust and xanthan gums, such as those described in US Serial No. 08/108,824 (Lang et al.), US 4,861 ,760 (Mazuel et al), US 4,136,173 (Pramoda et al), US 4,136, 177 (Lin et al.), and US 4,136, 178 (Lin et al). The contents of these patent applications and patents relating to the polymers cited above are hereby incorporated by reference herein.
The acidic drugs in the compositions of the present invention may also be encapsulated in microparticles such as microcapsules, microspheres, nanocapsule, nanospheres, and liposomes to improve comfort, and/or provide for sustained release.
The following examples are presented to illustrate further various aspects of the present invention, but are not intended to limit the scope of the invention in any respect.
EXAMPLE 1
The following formulations are representative of preferred compositions of the present invention.
Formulation (wt%)
Ingredient A B C
Sodium Diclofenac 0.1 — —
Sulfacetamide Sodium — 10 —
Suprofen — — 0.25
HPMC* 0.1 0.1 0.1
Tromethamine 2.0 2.0 2.0
Boric Acid 1.2 1.2 1.2
Vitamin E TPGS* * 3.0 3.0 3.0
Maπnitol 3.5 1 .6 3.6
Polyquad® 0.005 0.005 0.005
HCI/NaOH q.s. to pH 7.4 q.s. to pH q.s. to pH 7.4 7.4
Purified Water q.s. to 100% q.s. to 100% q.s. to 100%
* Hydroxypropyl Methyl Cellulose
* * Vitamin E Tocopheryl Polyethylene Glycol 1000 Succinate
Preparation;
The preparation of Formulation A is detailed below. Formulations B and C can be prepared in similar fashion.
Initially, a 10% stock solution of TPGS and a 2% stock solution of HPMC were prepared in water under constant stirring. Heat was applied if necessary to ensure complete dissolution.
To a tared glass vessel containing approximately 40 % final weight of purified water was added diclofenac-sodium. This mixture was stirred until the diclofenac was completely dissolved. The following ingredients were then added with stirring in the order given below, and each ingredient was completely dissolved before addition of the next ingredient: stock solution of vitamin E TPGS; tromethamine; boric acid; Polyquad®; mannitol; and stock solution of HPMC. Water was then added to bring the formulation to 95% of its final weight, and the pH of the formulation adjusted to between 7 and 7.4 using NaOH and/or HCI. Water was then added to bring the final weight to 100%. The resulting formulations were approximately isotonic (above 300 milliOsmoles per kilogram (mOsm/kg)).
EXAMPLE 2
The antimicrobial preservative effectiveness of the polymeric quaternary ammonium compound/boric acid combination of the present invention was determined using an organism challenge test according to the methods described in the United States Pharmacopeia (USP) and European Pharmacopoeia (Ph.Eur.). Samples were inoculated with known levels of gram-positive [Staphylococcus aureus ATCC 6538) and gram-negative {Pseudomonas aeruginosa ATCC 9027 and Escherichia coli ATCC 8739) vegetative bacteria, yeast (Candida albicans ATCC 10231 ) and mold (Aspergillus niger ATCC 16404) and sampled at specified intervals to determine if the antimicrobial preservative system was capable of killing or inhibiting the propagation of organisms purposely introduced into the formulation. The rate or level of antimicrobial activity determined compliance with the USP and/or Ph.Eur. preservative efficacy standards for ophthalmic preparations.
The compendial preservative standards for ophthalmic preparations are presented below:
For Bacteria:
Log Reduction of Organism Population
Time Pull USP Ph.Eur. Ph.Eur.
A B (Target) (Min)
6 hours - 2 -
24 hours - 3 1
7 days - - 3
14 days 3 - -
28 days Nl NR Nl For Fungi:
Time Pull USP Ph.Eur. Ph.Eur. I
A B (Target) (Min)
7 days - 2 -
14 days Nl - 1
28 days Nl Nl Nl
NR = No organisms recovered Nl = No increase at this or any following time pulls
= No requirement at this time pull
The results of the preservative challenge study conducted on Formulation A are shown below in Table 1. These results illustrate that an ophthalmic formulation of an acidic drug can be globally preserved, that is, can comply with the USP and Ph.Eur. A preservative effectiveness requirements for ophthalmic preparations, using a combination of a polymeric quaternary ammonium compound and boric acid.
Table 1
Preservative Challenge Results for Formulation A
TEST ORGANISM INITIAL Number of M croorganisms Per Milliliter* COUNT
6Hr 24 Hr Day 7 Day 14 Day 21 Day 28
S. aureus 1.5 X 106 <10 <10 <10 <10 <10 <10
P. aeruginosa 1.0 X 106 <10 <10 <10 <10 <10 <10
E. coli 1.1 X 106 <10 <10 <10 <10 <10 <10
C. albicans 1.2 X 106 6.3 X 105 4.1 X 104 4.4 X 102 <10 <10 <10
A. niger 1.3 X 106 1.4 X 106 3.9 X 104 2.5 X 102 8.0 X 101 6.5 X 101 <10
"Limit of detection: < 10 CFU/mL The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative in all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.

Claims

WHAT IS CLAIMED IS:
1. A preserved storage stable ophthalmic composition comprising a therapeutically effective amount of one or more acidic ophthalmic agents, a preservative-effective amount of a combination of an antimicrobial polymeric quaternary ammonium compound and boric acid, and an ophthalmically acceptable vehicle.
2. The composition of Claim 1 wherein the acidic ophthalmic agent is selected from the group consisting of anti-glaucoma, non-steroidal anti¬ inflammatory, anti-bacterial, anti-infective and diagnostic agents.
3. The composition of Claim 2 wherein the ophthalmic agent is a non¬ steroidal anti-inflammatory agent.
4. The composition of Claim 3 wherein the non-steroidal anti-inflammatory agent comprises an aryl- or heteroaryl-alkanoic acid, or an ophthalmically acceptable salt, ester, amide, or prodrug thereof.
5. The composition of Claim 4 wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of: diclofenac, flurbiprofen, suprofen, bromfenac, keterolac, indomethacin, ketaprofen, and ophthalmically acceptable salts, esters, amides or prodrugs thereof.
6. The composition of Claim 5 wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of diclofenac and its ophthalmically acceptable salts, esters, amides, or prodrugs thereof.
7. The composition of Claim 5 wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of suprofen and its ophthalmically acceptable salts, esters, amides, or prodrugs thereof.
8. The composition of Claim 5 wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of bromfenac and its ophthalmically acceptable salts, esters, amides, or prodrugs thereof.
9. The composition of Claim 8 wherein the antimicrobial polymeric quaternary ammonium compound is polyquaternium-1 .
10. The composition of Claim 9 wherein the polyquaternium-1 has a number average molecular weight from 2,000 to 30,000.
1 1. The composition of Claim 10 wherein the polyquaternium-1 has a number average molecular weight from 3,000 to 14,000.
12. The composition of Claim 1 wherein the concentration of the antimicrobial polymeric quaternary ammonium compound is between about 0.00001 and about 3 percent by weight.
13. The composition of Claim 12 wherein the concentration of the antimicrobial polymeric quaternary ammonium compound is between about 0.001 and about 0.1 percent by weight.
14. The composition of Claim 13 wherein the concentration of the antimicrobial polymeric quaternary ammonium compound is between about 0.001 and about 0.05 percent by weight.
15. The composition of Claim 1 wherein the ophthalmically active forms of boric acid are selected from the group consisting of boric acid, ophthalmically acceptable acid addition salts of boric acid and borate-polyol complexes.
16. The composition of Claim 1 wherein the concentration of boric acid is between about 0.3 and about 6 percent by weight.
17. The composition of Claim 16 wherein the concentration of boric acid or ophthalmically active forms thereof is between about 0.3 and about 3 percent by weight.
18. The composition of Claim 17 wherein the concentration of boric acid or ophthalmically active forms thereof is between about 0.5 and about 2 percent by weight.
19. The composition of Claim 1 5 wherein the ophthalmically active forms of boric acid are water soluble borate-polyol complexes having a molar ratio of borate to polyol from 1 : 1 to 1 :10.
20. A method for treating or controlling ocular inflammation, comprising the topical ocular application of the composition of Claim 3.
21 . The method of Claim 20, wherein the non-steroidal anti-inflammatory agent comprises an aryl- or heteroaryl- alkanoic acid, or an ophthalmically acceptable salt, ester, amide or prodrug thereof.
22. The method of Claim 21 wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of diclofenac and its ophthalmically acceptable salts, esters, amides or prodrugs.
23. The method of Claim 21 wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of suprofen and its ophthalmically acceptable salts, esters, amides or prodrugs.
24. The method of Claim 21 wherein the non-steroidal anti-inflammatory agent is selected from the group consisting of bromfenac and its ophthalmically acceptable salts, esters, amides or prodrugs.
25. A globally preserved ophthalmic formulation comprising diclofenac or an ophthalmically acceptable salt, ester, amide or prodrug thereof, and which meets USP and Ph.Eur. preservative effectiveness requirements using a combination of an antimicrobial polymeric quaternary ammonium compound and boric acid.
26. The formulation of Claim 25 wherein the formulation comprises sodium diclofenac, hydroxypropylmethyl cellulose, tromethamine, boric acid, mannitol, Polyquad® and a comfort-enhancing agent.
PCT/US1995/014910 1994-11-16 1995-11-16 Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds WO1996014829A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DE69522094T DE69522094T2 (en) 1994-11-16 1995-11-16 PRESERVATIVE-BASED OPHTALMICALLY APPLICABLE COMPOSITIONS CONTAINING QUATERNARY POLYMER-AMMONIUM COMPOUNDS
EP95939996A EP0739197B1 (en) 1994-11-16 1995-11-16 Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
DK95939996T DK0739197T3 (en) 1994-11-16 1995-11-16 Preserved ophthalmic drug preparations containing polymeric quaternary ammonium compounds
CA002180554A CA2180554C (en) 1994-11-16 1995-11-16 Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
JP8509750A JP2954356B2 (en) 1994-11-16 1995-11-16 Preserved ophthalmic drug composition containing a polymeric quaternary ammonium compound
AT95939996T ATE203897T1 (en) 1994-11-16 1995-11-16 PRESERVATIVELY CONTAINING OPHTHALMIC MEDICINAL COMPOSITIONS CONTAINING QUATERNARY POLYMER AMMONIUM COMPOUNDS
AU41622/96A AU686917B2 (en) 1994-11-16 1995-11-16 Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
HK98113829A HK1012556A1 (en) 1994-11-16 1998-12-17 Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
GR20010401480T GR3036622T3 (en) 1994-11-16 2001-09-17 Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/340,763 1994-11-16
US08/340,763 US5603929A (en) 1994-11-16 1994-11-16 Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds

Publications (1)

Publication Number Publication Date
WO1996014829A1 true WO1996014829A1 (en) 1996-05-23

Family

ID=23334841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/014910 WO1996014829A1 (en) 1994-11-16 1995-11-16 Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds

Country Status (13)

Country Link
US (2) US5603929A (en)
EP (1) EP0739197B1 (en)
JP (1) JP2954356B2 (en)
AT (1) ATE203897T1 (en)
AU (1) AU686917B2 (en)
CA (1) CA2180554C (en)
DE (1) DE69522094T2 (en)
DK (1) DK0739197T3 (en)
ES (1) ES2160722T3 (en)
GR (1) GR3036622T3 (en)
HK (1) HK1012556A1 (en)
PT (1) PT739197E (en)
WO (1) WO1996014829A1 (en)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006381A1 (en) * 1996-08-09 1998-02-19 Alcon Laboratories, Inc. Preservative systems for pharmaceutical compositions containing cyclodextrins
WO2002049615A2 (en) * 2000-12-21 2002-06-27 Alcon, Inc. Artificial tear composition containing a combination of three demulcents
WO2002087326A1 (en) * 2001-04-30 2002-11-07 Allergan, Inc. Compositions including vitamin-based surfactants ad methods for using same
WO2003026420A1 (en) * 2001-09-17 2003-04-03 Menicon Co., Ltd. Bactericidal solutions
EP1586316A1 (en) * 2003-01-21 2005-10-19 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
US8722735B2 (en) 2008-03-17 2014-05-13 Alcon Research, Ltd. Pharmaceutical compositions having desirable bioavailability
US9017725B2 (en) 2009-06-09 2015-04-28 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
CN104812370A (en) * 2012-11-19 2015-07-29 博士伦公司 Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid
US9107888B2 (en) 2011-01-18 2015-08-18 Senju Pharmaceutical Co., Ltd. Aqueous liquid bromfenac composition having preservative efficacy
US10265375B2 (en) 2007-10-08 2019-04-23 Aurinia Pharmaceuticals Inc. Ophthalmic compositions
US10632202B2 (en) 2016-03-04 2020-04-28 Johnson & Johnson Consumer Inc. Preservative containing compositions
US11622991B2 (en) 2017-05-12 2023-04-11 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505953A (en) * 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5683993A (en) * 1995-06-22 1997-11-04 Ciba Vision Corporation Compositions and methods for stabilizing polymers
JP2000505486A (en) * 1996-02-14 2000-05-09 アルコン ラボラトリーズ，インコーポレイテッド Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobial agents
CN1157227C (en) * 1996-12-13 2004-07-14 阿尔康实验室公司 Use of low molecular weight amino alcohols in ophthalmic compositions
ATE250923T1 (en) 1997-07-29 2003-10-15 Alcon Lab Inc EYE DRUGS CONTAINING GALACTOMANNAN POLYMERS AND BORATE
ATE504644T1 (en) 1997-11-26 2011-04-15 Abbott Medical Optics Inc USE OF HYDROXYPROPYLMETHYL CELLULOSE IN A CONTACT LENS CLEANER
US6063745A (en) * 1997-11-26 2000-05-16 Allergan Mutli-purpose contact lens care compositions
JPH11249087A (en) * 1997-12-18 1999-09-17 Tome:Kk Light agent for contact lens
JP2006111636A (en) * 1997-12-26 2006-04-27 Astellas Pharma Inc Sustained release pharmaceutical composition
US7678836B2 (en) * 1999-11-04 2010-03-16 Fxs Ventures, Llc Method for rendering a contact lens wettable
EP1250133B1 (en) * 2000-01-25 2005-03-30 Alcon Inc. Ophthalmic anti-allergy compositions suitable for use with contact lenses
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
US20060073184A1 (en) * 2004-09-29 2006-04-06 Bausch & Lomb Inc. Viscoelastic composition, methods of use and packaging device with anti-oxidant
CN1993118B (en) 2004-11-05 2010-06-16 千寿制药株式会社 Aqueous eye drops with accelerated intraocular migration permeability
JP5108234B2 (en) * 2005-02-07 2012-12-26 日本特殊陶業株式会社 Micro heater and sensor
US7947010B2 (en) 2005-07-08 2011-05-24 Depuy Products, Inc. Composition and system for wound decontamination
US20100130580A1 (en) * 2006-01-25 2010-05-27 Aciex Therapeutics, Inc. Formulations and Methods for Treating Dry Eye
CA2621616A1 (en) * 2007-02-19 2008-08-19 Alcon Research, Ltd. Topical gatifloxacin formulations
US7705112B2 (en) 2007-04-17 2010-04-27 Abbott Medical Optics Inc. Polyquaternium-1 synthesis methods
CA2687717A1 (en) * 2007-05-24 2008-12-18 Aciex Therapeutics, Inc. Formulations and methods for treating dry eye
BRPI0908502A2 (en) * 2008-02-21 2017-05-23 Ista Pharmaceuticals ophthalmic aines as adjuvants
US9192571B2 (en) 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
PT2254549E (en) 2008-03-17 2014-01-30 Alcon Res Ltd Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI454289B (en) * 2008-04-03 2014-10-01 Alcon Res Ltd Use of cis-diol-containing polymer to inhibit the uptake of cationic biocides into hydrogel biomaterials
TW201038295A (en) 2009-04-17 2010-11-01 Alcon Res Ltd Aqueous ophthalmic compositions containing anionic therapeutic agents
TWI489997B (en) 2009-06-19 2015-07-01 Alcon Res Ltd Aqueous pharmaceutical compositions containing borate-polyol complexes
WO2014204952A1 (en) 2013-06-19 2014-12-24 Sentiss Research Center Stable bromfenac solution
BR112016003692B1 (en) 2013-08-20 2022-02-08 3M Innovative Properties Company POLYESTER BORO-SILANE COMPLEX
WO2015087267A2 (en) 2013-12-12 2015-06-18 Sentiss Pharma Private Limited Stable bromfenac ophthalmic solution
US20230159202A1 (en) * 2021-11-23 2023-05-25 Bausch + Lomb Ireland Limited Method for making a preservative-free packaged ophthalmic device product

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0076136A2 (en) * 1981-09-28 1983-04-06 Alcon Laboratories, Inc. Ophthalmic solutions
EP0306984A1 (en) * 1987-09-11 1989-03-15 Syntex (U.S.A.) Inc. Preservative system for ophtalmic formulations
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
WO1994015597A1 (en) * 1993-01-11 1994-07-21 Allergan, Inc. Ophthalmic compositions comprising benzyllauryldimethylammonium chloride

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931319A (en) * 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4027020A (en) * 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US4136178A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Locust bean gum therapeutic compositions
FR2508440B1 (en) * 1981-06-25 1985-11-08 Saint Gobain Isover PROCESS FOR THE PREPARATION OF ORTHOHYDROXYBENZYL ALCOHOLS
US4525346A (en) * 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4836986A (en) * 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
FR2588189B1 (en) * 1985-10-03 1988-12-02 Merck Sharp & Dohme LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION
US4822819A (en) * 1986-11-07 1989-04-18 Alcon Laboratories, Inc. Use of trimoprostil and derivatives in glaucoma therapy
US4822820A (en) * 1986-11-24 1989-04-18 Alcon Laboratories, Inc. Use of tri-methyl PG-F2 a and derivatives in glaucoma therapy
US5110493A (en) * 1987-09-11 1992-05-05 Syntex (U.S.A.) Inc. Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
US5149693A (en) * 1988-03-09 1992-09-22 Alcon Laboratories, Inc. Combination of tobramycin and fluorometholone for topical ophthalmic use
US5149694A (en) * 1988-03-09 1992-09-22 Alcon Laboratories, Inc. Combination of tobramycin and dexamethasone for topical ophthalmic use
US5173507A (en) * 1988-07-18 1992-12-22 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5037647A (en) * 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5145643A (en) * 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
EP0639070B2 (en) * 1992-05-06 2010-09-08 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5300287A (en) * 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0076136A2 (en) * 1981-09-28 1983-04-06 Alcon Laboratories, Inc. Ophthalmic solutions
EP0306984A1 (en) * 1987-09-11 1989-03-15 Syntex (U.S.A.) Inc. Preservative system for ophtalmic formulations
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
WO1994015597A1 (en) * 1993-01-11 1994-07-21 Allergan, Inc. Ophthalmic compositions comprising benzyllauryldimethylammonium chloride

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985310A (en) * 1996-08-09 1999-11-16 Alcon Laboratories, Inc. Preservative systems for pharmaceutical compositions containing cyclodextrins
WO1998006381A1 (en) * 1996-08-09 1998-02-19 Alcon Laboratories, Inc. Preservative systems for pharmaceutical compositions containing cyclodextrins
WO2002049615A2 (en) * 2000-12-21 2002-06-27 Alcon, Inc. Artificial tear composition containing a combination of three demulcents
WO2002049615A3 (en) * 2000-12-21 2003-01-16 Alcon Inc Artificial tear composition containing a combination of three demulcents
US6620797B2 (en) 2000-12-21 2003-09-16 Alcon, Inc. Artificial tear composition containing a combination of three demulcents
US7923469B2 (en) 2001-04-30 2011-04-12 Allergen, Inc. Compositions including vitamin-based surfactants and methods for using same
WO2002087326A1 (en) * 2001-04-30 2002-11-07 Allergan, Inc. Compositions including vitamin-based surfactants ad methods for using same
WO2003026420A1 (en) * 2001-09-17 2003-04-03 Menicon Co., Ltd. Bactericidal solutions
US8871813B2 (en) 2003-01-21 2014-10-28 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
CN100341498C (en) * 2003-01-21 2007-10-10 千寿制药株式会社 Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
EP1586316A1 (en) * 2003-01-21 2005-10-19 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
US8129431B2 (en) 2003-01-21 2012-03-06 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
US8497304B2 (en) 2003-01-21 2013-07-30 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
US8669290B2 (en) 2003-01-21 2014-03-11 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
US8754131B2 (en) 2003-01-21 2014-06-17 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
US9144609B2 (en) 2003-01-21 2015-09-29 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
EP1586316A4 (en) * 2003-01-21 2007-06-27 Senju Pharma Co Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
US8927606B1 (en) 2003-01-21 2015-01-06 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
US9561277B2 (en) 2003-01-21 2017-02-07 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid
US10973871B2 (en) 2007-10-08 2021-04-13 Aurinia Pharmaceuticals, Inc. Ophthalmic compositions
US10265375B2 (en) 2007-10-08 2019-04-23 Aurinia Pharmaceuticals Inc. Ophthalmic compositions
US8754123B2 (en) 2008-03-17 2014-06-17 Alcon Research, Ltd. Pharmaceutical compositions having desirable bioavailability
US9144561B2 (en) 2008-03-17 2015-09-29 Alcon Research, Ltd. Pharmaceutical compositions having desirable bioavailability
US8722735B2 (en) 2008-03-17 2014-05-13 Alcon Research, Ltd. Pharmaceutical compositions having desirable bioavailability
US9017725B2 (en) 2009-06-09 2015-04-28 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
US9107888B2 (en) 2011-01-18 2015-08-18 Senju Pharmaceutical Co., Ltd. Aqueous liquid bromfenac composition having preservative efficacy
US9561280B2 (en) 2011-01-18 2017-02-07 Senju Pharmaceutical Co., Ltd. Aqueous liquid bromfenac composition having preservative efficacy
CN104812370A (en) * 2012-11-19 2015-07-29 博士伦公司 Aqueous liquid composition containing 2-amino-3-(4-bromobenzoyl) phenylacetic acid
CN104812370B (en) * 2012-11-19 2018-05-08 博士伦公司 Include the aqueous liquid composition of 2- amino -3- (4- benzoyl bromides) phenylacetic acid
US10632202B2 (en) 2016-03-04 2020-04-28 Johnson & Johnson Consumer Inc. Preservative containing compositions
US11202832B2 (en) 2016-03-04 2021-12-21 Johnson & Johnson Consumer Inc. Preservative containing compositions
US11622991B2 (en) 2017-05-12 2023-04-11 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Also Published As

Publication number Publication date
US5603929A (en) 1997-02-18
JPH09503791A (en) 1997-04-15
HK1012556A1 (en) 1999-08-06
DE69522094T2 (en) 2001-11-22
GR3036622T3 (en) 2001-12-31
EP0739197A1 (en) 1996-10-30
US5653972A (en) 1997-08-05
AU4162296A (en) 1996-06-06
DE69522094D1 (en) 2001-09-13
AU686917B2 (en) 1998-02-12
EP0739197B1 (en) 2001-08-08
ES2160722T3 (en) 2001-11-16
DK0739197T3 (en) 2001-10-29
CA2180554C (en) 2001-08-21
CA2180554A1 (en) 1996-05-23
PT739197E (en) 2001-12-28
JP2954356B2 (en) 1999-09-27
ATE203897T1 (en) 2001-08-15

Similar Documents

Publication Publication Date Title
AU686917B2 (en) Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US5558876A (en) Topical ophthalmic acidic drug formulations
US5886030A (en) Use of vitamin E tocopheryl derivatives in ophthalmic compositions
US5110493A (en) Ophthalmic NSAID formulations containing a quaternary ammonium preservative and a nonionic surfactant
US6995186B2 (en) Olopatadine formulations for topical administration
US5414011A (en) Preservative system for ophthalmic formulations
RU2563125C2 (en) Aqueous pharmaceutical compositions, containing borate-polyol complexes
ES2207748T3 (en) PRESERVING SYSTEMS FOR PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLODEXTRINES.
AU2002310461A1 (en) Olopatadine formulations for topical administation
EP1250133B1 (en) Ophthalmic anti-allergy compositions suitable for use with contact lenses
US6743439B1 (en) Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
JP4524538B2 (en) Ophthalmic composition
CA2758858C (en) Aqueous ophthalmic compositions containing anionic therapeutic agents
MXPA96000140A (en) Use of tocyferyl derivatives of vitamin e in oftalmi compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2180554

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995939996

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 1995939996

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1995939996

Country of ref document: EP